BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/7/2026 9:40:19 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-03-18 06:42 |
|
Peer-Review Started |
|
2026-03-18 06:42 |
|
First Decision by Editorial Office Director |
|
2026-04-10 10:09 |
|
Return for Revision |
|
2026-04-13 11:51 |
|
Revised |
|
2026-04-20 08:09 |
|
Publication Fee Transferred |
|
2026-04-27 04:51 |
|
Second Decision by Editor |
|
2026-05-13 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-13 08:06 |
|
Articles in Press |
|
2026-05-13 08:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-13 06:06 |
|
Publish the Manuscript Online |
|
2026-08-07 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mi-Ran Han, Ji Eun Shin, Sung Hee Lim, Jeeyun Lee and Seung Tae Kim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Seung Tae Kim, PhD, Professor, Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-Gu, Seoul 06351, South Korea. shty1@skku.edu |
| Key Words |
Gastric cancer; Claudin 18.2; Ramucirumab; Paclitaxel; Biomarker |
| Core Tip |
Claudin expression is an established biomarker for targeted therapy in gastric cancer; however, its clinical relevance remains uncertain. In this retrospective study, claudin expression was not associated with survival or treatment response in patients with advanced gastric cancer who were treated with ramucirumab plus paclitaxel. These findings highlight a key distinction between intrinsic tumor biomarkers and therapies targeting the tumor microenvironment. Claudin expression should not be used to guide second-line anti-angiogenic treatments, emphasizing the need for mechanism-based biomarker selection in precision oncology. |
| Publish Date |
2026-08-07 09:40 |
| Citation |
Han MR, Shin JE, Lim SH, Lee J, Kim ST. Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer. World J Gastrointest Oncol 2026; 18(8): 121158
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i8/121158.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i8.121158 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
